Immunocore Holdings plc (IMCR) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.08: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 11.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 22.00; Below-average business quality.
Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp), the first FDA-approved TCR bispecific therapy for metastatic uveal melanoma, approved in 39 countries and commercially launched in 30. Revenue is generated from KIMMTRAK sales through a hybrid... Read more
Sell if holding. Engine safety override at $28.08: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 11.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 22.00; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Score 5.6/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductKIMMTRAK10-K Item 1A: 'Our ability to generate significant medicine revenues and to achieve commercial success in the near-term will initially depend on our ability to continue to commercialize KIMMTRAK.'
Material Events(8-K, last 90d)
- 2026-01-30Item 5.02MEDIUMDavid Berman, Head of Research & Development, resigned effective February 27, 2026 to pursue another opportunity. No disagreement cited. Company will not seek a direct replacement but will streamline and leverage its existing R&D structure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.08: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 11.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 22.00; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Prior stop was $26.82. Score 5.6/10, moderate confidence.
Take-profit target: $55.56 (+98.0% upside). Prior stop was $26.82. Stop-loss: $26.82.
Concentration risk — Product: KIMMTRAK; Quality below floor (3.8 < 4.0).
Immunocore Holdings plc trades at a P/E of N/A (forward -19.9). TrendMatrix value score: 8.6/10. Verdict: Sell.
23 analysts cover IMCR with a consensus score of 4.1/5. Average price target: $64.
What does Immunocore Holdings plc do?Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp), the first FDA-approved TCR bispecific therapy for...
Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp), the first FDA-approved TCR bispecific therapy for metastatic uveal melanoma, approved in 39 countries and commercially launched in 30. Revenue is generated from KIMMTRAK sales through a hybrid in-house/contracted sales model in the US and Europe.